MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Harrow Health Retained Earnings 2011-2026 | HROW
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Harrow Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -157 M | -151 M | -134 M | -109 M | -95.4 M | -77.4 M | -74 M | -74.2 M | -88.8 M | -76.9 M | -57.8 M | -41.9 M | -31.7 M | -24.1 M | -18.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -18.5 M | -157 M | -80.8 M |
Quarterly Retained Earnings Harrow Health
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -163 M | -164 M | -169 M | -151 M | -158 M | -154 M | -147 M | -134 M | -125 M | -120 M | -116 M | -109 M | -111 M | -104 M | -97.8 M | -95.4 M | -88 M | -79.7 M | -77.2 M | -77.4 M | -77.4 M | -77.4 M | -77.4 M | -74 M | -74 M | -74 M | -74 M | -74.2 M | -74.2 M | -74.2 M | -74.2 M | -88.8 M | -88.8 M | -88.8 M | -88.8 M | -76.9 M | -76.9 M | -76.9 M | -76.9 M | -57.8 M | -57.8 M | -57.8 M | -57.8 M | -41.9 M | -41.9 M | -41.9 M | -41.9 M | -31.7 M | -31.7 M | -31.7 M | 25.6 M | - | - | 21.4 | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25.6 M | -169 M | -84.6 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-472 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 2.76 | 2.6 % | $ 1.42 B |  Canada |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.15 | -2.48 % | $ 44.3 M | USA |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 5.91 | 0.17 % | $ 2.16 B | Canada |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.2 | 5.26 % | $ 129 M | Canada |
 |
Jupiter Wellness
JUPW
|
-183 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.51 | 3.42 % | $ 402 M | Canada |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.54 | 1.99 % | $ 3.37 M | Canada |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
-661 M | $ 5.08 | 8.32 % | $ 328 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 8.35 | -5.22 % | $ 428 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-353 M | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 2.52 | 0.8 % | $ 332 M | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 24.9 | 0.73 % | $ 1.15 B | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Relmada Therapeutics
RLMD
|
-698 M | $ 7.37 | -1.47 % | $ 291 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
-703 M | $ 18.14 | 0.72 % | $ 116 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-385 M | $ 1.07 | -3.6 % | $ 53.4 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 7.15 | 4.23 % | $ 4.42 B | Canada |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-958 M | $ 8.49 | -1.62 % | $ 743 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 2.65 | 15.22 % | $ 3.29 M | USA |
 |
Veru
VERU
|
-295 M | $ 2.43 | -0.41 % | $ 328 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 14.87 | 1.29 % | $ 17.8 B | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 3.72 | 1.64 % | $ 86.3 M | Canada |
 |
cbdMD
YCBD
|
-182 M | $ 0.81 | 2.28 % | $ 3.49 M | USA |
 |
Zomedica Corp.
ZOM
|
-300 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-403 M | $ 0.94 | 2.74 % | $ 33.8 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-47.2 M | $ 0.67 | -0.54 % | $ 2.88 M |  China |
 |
TherapeuticsMD
TXMD
|
-952 M | $ 2.19 | 5.8 % | $ 25.3 M | USA |